Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind U.S. Phase II study in 79 patients (ages 65-75) with chronic
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury